Systematic review and meta-analysis: Proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay - Results from the Cochrane Collaboration

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 3, 2005, Pages 169-174

  Leontiadis, G I ^a   Sharma, V K ^b   Howden, C W ^c  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b MAYO CLINIC   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PLACEBO; PROTON PUMP INHIBITOR;

ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; COCHRANE LIBRARY; HOSPITALIZATION; HUMAN; LENGTH OF STAY; META ANALYSIS; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANTI-ULCER AGENTS; BLOOD TRANSFUSION; HUMANS; LENGTH OF STAY; PEPTIC ULCER HEMORRHAGE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS;

EID: 23844454036     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02546.x     Document Type: Article

References (17)

1. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-46.
2. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004, issue 3. Article no: CD002094, pub2 (DOI: 10.1002/14651858.CD002094. pub2).
3. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. Br Med J 2005; 330: 568-70.
4. Leontiadis GI, Sharma VK, Howden CW. Enhanced efficacy of proton pump inhibitor therapy for peptic ulcer bleeding in Asia: a post hoc analysis from the Cochrane Collaboration systematic review and meta-analysis. Aliment Pharmacol Ther 2005; 21: 1055-61.
5. Coraggio F, Rotondano G, Marmo R, et al. Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998; 10: 673-6.
6. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997; 32: 328-33.
7. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17: 211-6.
8. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: 1054-8.
9. Lanas A, Artal A, Bias JM, Arroyo MT, Lopez-Zaborras J, Sainz R. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol 1995; 21: 103-6.
10. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6.
11. Pérez Flores R, García Molinero MJ, Herrero Quirós C, et al. Tratamiento de la hemorragia digestive alta de origen péptico: ranitidina intravenosa versus omeprazol intravenoso. Rev Esp Enferm Dig 1994; 86: 637-41.
12. Villanueva C, Balanzo J, Torras X, et al. Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Endoscopy 1995; 27: 308-12.
13. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001; 111: 280-4.
14. Lam SK, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 1980; 21: 324-8.
15. van Herwaarden MA, Samson M, van Nispen CHM, Mulder PGH, Smout AJPM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: 731-40.
16. Caraco Y, Lagerstrom PO, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: 157-67.
17. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996; 60: 396-404.